Validity and Characterization of Time to Symptom Resolution Outcome Measures in the ACTIV-2/A5401 Outpatient COVID-19 Treatment Trial.

Kara W Chew Carlee B MoserEunice YehDavid A WohlEric S DaarJustin RitzArzhang Cyrus JavanJoseph J EronJudith S CurrierDavey M SmithMichael D Hughesnull null

Published in: The Journal of infectious diseases (2023)

NCT04518410.

Keyphrases

coronavirus disease
sars cov
clinical trial
study protocol
phase ii
single molecule
combination therapy
respiratory syndrome coronavirus